Pacira Biosciences Inc
NASDAQ:PCRX
Pacira Biosciences Inc
Cash from Operating Activities
Pacira Biosciences Inc
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Pacira Biosciences Inc
NASDAQ:PCRX
|
Cash from Operating Activities
$154.6m
|
CAGR 3-Years
26%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Operating Activities
$23.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Operating Activities
$13.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
17%
|
CAGR 10-Years
12%
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Operating Activities
$8.7B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Operating Activities
$13B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Operating Activities
$3.7B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-4%
|
See Also
What is Pacira Biosciences Inc's Cash from Operating Activities?
Cash from Operating Activities
154.6m
USD
Based on the financial report for Dec 31, 2023, Pacira Biosciences Inc's Cash from Operating Activities amounts to 154.6m USD.
What is Pacira Biosciences Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
26%
Over the last year, the Cash from Operating Activities growth was 6%. The average annual Cash from Operating Activities growth rates for Pacira Biosciences Inc have been 26% over the past three years , 26% over the past five years .